Will a new FDA user fee discourage innovation in medical devices ?

More medical device companies have been using an alternative pathway to get innovative products on the market faster, but a new user fee on industry could affect the use of this pathway.

The “de novo” classification pathway has been used to get devices on the U.S. market such as Accelerate Diagnostics Inc.'s PhenoTest BC Kit, the first test to identify organisms that cause bloodstream infections and provide information on the correct antibiotics for treatment. De novo is a way to get products on the market without going through the Food and Drug Administration’s most stringent review process, known as premarket approval.

However, if companies have to pay a new fee that is seen as relatively burdensome, it could dissuade applicants from seeking de novo classification...

Latest news

International -
Management de la qualité : l’ISO 9004 relookée

« Petite sœur » de l’ISO 9001, la norme volontaire ISO 9004 vient d’être révisée. Elle donne des lignes directrices pour déployer un management de la qualité en vue d’obtenir des performances durables dans l’organisation. Comme l’ISO 9001 en 2015, la norme volontaire internationale ISO 9004, l’une de ses petites sœurs, vient d’être relookée. Orchestrée par le comité technique TC 176 de l’ISO (Organisation internationale de normalisation), dans lequel AFNOR représentait la France, la révision a débouché sur un texte publié en avril 2018, disponible dans la collection AFNOR ici neuf ans après...

FDA Clears FlowTriever, First Device to Pull Blood Clots from Lungs

Inari Medical of Irvine, California won the first FDA clearance for a thrombectomy device to be used for treatment of pulmonary embolisms. The FlowTriever went through a clinical study involving 106 patients with acute pulmonary embolism and RV/LV (right ventricular/left ventricular) ratio of at least 0.9 that were treated using the device instead of commonly used clot busters. According to the company, “the mean RV/LV ratio in the study decreased from a baseline of 1.53 to 1.15 at 48 hours postprocedure, a difference of 0.39 (p<0.0001). The study also demonstrated excellent safety at 30...

International -
Real World Data Could Give Edwards Edge in TAVR

TAVR pioneer Edwards Lifesciences has released positive 30-day data of its Sapien 3 valve at EuroPCR. Edwards Lifesciences is continuing to strengthen its position in the transcatheter aortic valve replacement(TAVR) market by revealing real world data for the Sapien 3 valve. The Irvine, CA-based company presented positive 30-data of the device at EuroPCR . The propensity-matched analysis compared real-world data collected from the Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry with outcomes of patients enrolled in the...



Make sure you don't miss latest news, stay tuned!